To determine the effect of two different graft-versushost disease (GVHD) prophylactic regimens -cyclosporine with short course of methotrexate (CYA-MTX) and cyclosporine with prednisone (CYA-PRED) -on the incidence of chronic GVHD (cGVHD), we retrospectively reviewed the outcomes of 196 consecutive allogeneic related blood and marrow transplants performed at our institution utilizing one of these regimens. CYA-PRED was given to patients who were transplanted more recently because of concern about the increased risk of veno-occlusive disease of the liver, increased mucositis, and slower engraftment in patients receiving CYA-MTX. Prophylaxis with CYA-PRED was associated with a higher risk of development of cGVHD (risk ratio (RR) 3.5; 95% confidence intrerval (CI), 2.2-5.4). The proportion of patients with extensive disease among those developing cGVHD was higher in the CYA-PRED group (71%) than in the CYA-MTX group (57%), although this difference was not statistically significant. The cumulative probability of extensive cGVHD at 2 years was higher in the CYA-PRED group (RR 4.2, 95% CI, 2.4-7.4). Development of acute GVHD and cytomegalovirus mismatch were independent predictors of increased risk of cGVHD. We conclude that GVHD prophylaxis with CYA-PRED is associated with a higher overall rate of cGVHD compared to CYA-MTX. The type of GVHD prophylaxis should be considered when comparing the incidence of cGVHD reported in different studies. Bone Marrow Transplantation (2001) 27, 1133-1140. Keywords: allogeneic bone marrow transplantation; CYA; cytomegalovirus; MTX; prednisone; survival The number of allogeneic bone marrow transplantations (BMT) has increased steadily over the past three decades.
malignancies. Graft-versus-host disease (GVHD), both acute and chronic, is an important complication of allogeneic transplants. Moderate-to-severe GVHD occurs in as many as one-half of the recipients of HLA-identical sibling transplants despite post-transplantation prophylaxis of GVHD. 2 Chronic GVHD develops in a significant number of these patients. For patients who survive the initial 2 to 3 months after transplantation, development of chronic GVHD has the greatest effect on their subsequent quality of life. The incidence of chronic GVHD reported in previous studies varied from 30% to 60%. 3, 4 GVHD alone or in combination with infection accounts for a significant number of late transplant-related deaths in patients free of disease.
Severe acute GVHD has a high mortality rate, and its prevention remains a cornerstone in the management of patients who have received a transplant. Considerable controversy exists about how best to prevent acute GVHD, and various pharmacologic and nonpharmacologic modalities have been tried. In vitro depletion of T lymphocytes from the marrow has been associated with a decreased incidence of GVHD, but it contributes to a higher rate of relapse and graft failure. 5 Various immunosuppressive drugs, alone or in combination, have been used for GVHD prophylaxis. Cyclophosphamide (CY) was one of the first agents used, but it has been supplanted by other drugs. 6, 7 Methotrexate (MTX) was used as a single agent until the advent of cyclosporine (CYA) in the early 1980s. Since then, several studies have compared the effect of these drugs, used alone or in combination.
Several randomized and nonrandomized trials have shown that prophylactic treatment with the combination of CYA and MTX decreases the incidence of acute GVHD compared with treatment with either drug alone. [8] [9] [10] [11] [12] Methylprednisolone has been used extensively in the treatment of acute and chronic GVHD. Several studies have examined the effect of the addition of prednisone (PRED) to the GVHD prophylactic regimen on the incidence of GVHD and long-term survival. The addition of PRED to CYA has been associated with a decrease in the incidence of acute GVHD, especially grade 2-3 GVHD. 13 However, in the same study, an increase was noted in the incidence of chronic GVHD with the addition of PRED. The overall relapse-free survival was marginally better in the group receiving PRED. Other investigators have studied the effect of the addition of PRED to the combination of CYA and MTX. [14] [15] [16] [17] An increase in the incidence of acute and chronic GVHD was noted in one study, 14 with no difference in survival, and in two other studies, no advantage was noted in either survival or the incidence of GVHD. 15, 16 In another study, an increase in the incidence of infection was noted with the addition of PRED, 18 but other studies did not confirm this observation. 13, 16 In a prospective study that compared CYA and PRED with CYA and MTX, Gondo et al 19 showed a lower incidence of chronic GVHD with the former combination, although other studies have noted a higher incidence of chronic GVHD with the CYA and PRED regimen. 13, 20 Chao et al 21 studied the effect of adding MTX to the combination of CYA and PRED in a randomized trial of GVHD prophylaxis and found that patients receiving all three drugs had a significantly lower incidence of acute GVHD of grades 2 to 4 than those receiving CYA and PRED. However, at 3 years, the difference in disease-free survival between the two treatment groups was not significant. Follow-up of these results suggested that there was no difference between these two combinations in the incidence of chronic GVHD. 22 Because of these conflicting results, we retrospectively studied the incidence of chronic GVHD in a group of HLAmatched related donor BMTs and compared the effect of two different prophylaxis regimens containing CYA in combination with either PRED or MTX.
Materials and methods

Patients
We retrospectively reviewed 269 consecutive allogeneic related blood and marrow transplants performed in 265 patients at our institution between 1982 and 1997. Included in the study were 196 transplants in which either CYA-MTX or CYA-PRED was given for prophylaxis of acute GVHD. Four of the transplants were second transplants and were excluded from the study. The median age of the patients (176 adults, 16 children) was 34 years (range, 6 months to 58 years). The patient group included 108 males (56%). The two treatment groups included patients with the diagnoses of acute lymphoblastic leukaemia, acute myelocytic leukaemia, chronic myelocytic leukaemia, aplastic anaemia, non-Hodgkin's lymphoma, myelodysplastic syndrome, Hodgkin's disease, multiple myeloma, and chronic lymphocytic leukemia. The two groups did not differ significantly except for disease types and conditioning chemotherapy (Table 1) . Of the 192 patients, 96 (50%) had nonadvanced disease (first remission or chronic myelocytic leukaemia chronic phase) and 96 had advanced disease. There was a complete HLA match in 175 of the transplant recipients; the other 17 had a one-antigen mismatch. CMV mismatch, defined as a seropositive donor and a seronegative recipient, was present in 37 recipients (19%). The conditioning regimen used most commonly (64%) was CY with fractionated TBI (1320 cGy). The other preparative regimens included BU/CY and VP-16/TBI. Post-transplantation immunosuppression was with CYA, 2.5 mg/kg twice daily, starting on day −1, and 1.5 mg twice daily thereafter to maintain blood levels of 100 to 300 mg/dl. The second agent was either MTX or PRED. MTX was given at a dose of 15 mg/m 2 on day 1 and 10 mg/m 2 on days 3, 6 and 11. PRED was given at a dose of 0.5 mg/kg on days 8 to 14 and 1 mg/kg from day 14 to 28, with taper thereafter as indicated. The decision regarding the type of GVHD prophylaxis was independent of the nature of underlying disease. Because of concern about increased risk of venoocclusive disease with MTX, 23 there was a shift in the policy regarding type of GVHD prophylaxis in 1994 and most patients who had a transplant thereafter until 1997 received CYA-PRED. Acute GVHD was treated with PRED at a dose of 1 to 2 mg/kg as soon as the diagnosis was confirmed. Twenty-nine patients (24 from the CYA-MTX group and five from the CYA-PRED group) did not survive beyond 60 days and, hence, were not evaluable for the incidence of chronic GVHD and were excluded from the analysis.
End points
The end points analysed were onset of acute GVHD and chronic GVHD, relapse, and treatment failure (relapse or death). Acute GVHD was graded 1 to 4 according to established criteria. 24, 25 Patients surviving longer than 21 days with evidence of engraftment were considered at risk for development of acute GVHD. Chronic GVHD was diagnosed according to the established clinical and histologic criteria in the 163 patients who survived beyond 60 days. Remission and relapse were defined by conventional criteria. Treatment-related mortality (TRM) was defined as death related directly to toxicity from the conditioning regimen or other causes related to the transplant process in patients free of disease (or both).
Statistical methods
Comparisons were made between prophylactic treatment groups for sex, pediatric age, disease type, HLA status, CMV mismatch, type of chronic GVHD, and severity of chronic GVHD using the 2 or Fisher exact test, as appropriate. Age and duration to onset of chronic GVHD by prophylaxis type were assessed with the Wilcoxon rank sum test. The cumulative probability of patient death, chronic GVHD development, acute GVHD development, relapse, and treatment-related mortality was assessed using Cox proportional hazards models. 26 The 1-year estimate and the 95% confidence interval (CI) for the estimate were calculated by the Kaplan-Meier survival method. 27 Timedependent Cox models were used to assess both chronic and acute GVHD development as possible risk factors. In all analyses involving development of chronic GVHD, only the 163 patients surviving to at least day 60 were included. All analyses were performed using the SAS statistical package. P р 0.05 was considered statistically significant.
The study protocol was reviewed and approved by the Institutional Review Board of Mayo Foundation. 
Results
Patients who survived at least 60 days were considered for the analysis of development of chronic GVHD (118 patients in the CYA-MTX group and 45 in the CYA-PRED group). The median post-transplantation follow-up for patients alive at latest follow-up was 49.1 months (range 2.5-154.7 months). Prophylaxis with CYA-PRED was associated with a higher risk of development of chronic GVHD (risk ratio, 3.5; 95% CI, 2.213-5.406; P Ͻ 0.0001). At 1 year after transplantation, the cumulative probability of chronic GVHD was 48.3% (95% CI, 37.3-57.3) for the CYA-MTX group, compared with 84.8% (95% CI, 67.7-93.4) for the CYA-PRED group (Table 2, Figure 1) . Among the 85 patients in whom chronic GVHD developed, 53 (62%) had extensive disease and 32 (38%) had limited disease. Patients in the CYA-PRED group were at significantly higher risk for development of extensive chronic GVHD, with multiorgan involvement, than those in the CYA-MTX group (risk ratio of 4.2 at 2 years post-transplantation; 95% CI, 2.4-7.4) ( Table 2) . Of the patients with acute GVHD, chronic GVHD (progressive) developed in 27 (32%), an intervening quiescent period occurred in 33 (39%), and signs and symptoms of chronic GVHD without any evidence of acute GVHD (de novo) developed in 25
Bone Marrow Transplantation (29%). In the CYA-PRED group, 47% of the patients had de novo type chronic GVHD, compared with 18% in the CYA-MTX group (P = 0.013) ( Table 2) .
As we reported previously, 28 lung involvement, mostly in the form of bronchiolitis obliterans, occurred more commonly in the CYA-PRED group than in the CYA-MTX group (cumulative probability at 1 year post-transplantation of 33.6% vs 10.1%; P Ͻ 0.001). Liver involvement was seen more often in the CYA-PRED group (P Ͻ 0.001). The cumulative probability of liver involvement at 1 year after transplantation was 33% in the CYA-MTX group, compared with 77.5% in the CYA-PRED group (Table 2) . These patterns included an increase in alkaline phosphatase concentration alone or in combination with an increase in the concentrations of transaminases and bilirubin. Involvement of the gut was also more frequent in the CYA-PRED group than in the CYA-MTX group (21% vs 6.2% at 1 year after transplantation). Involvement of the skin was also more common in the CYA-PRED group than in the CYA-MTX group (80.5% vs 39.4%). The median time to clinical onset of chronic GVHD was 100 days for the CYA-PRED group and 135 days for the CYA-MTX group (P Ͻ 0.001).
In multivariate modeling that included the type of GVHD prophylaxis and the occurrence of acute GVHD, acute GVHD was an independent risk factor for development of chronic GVHD (risk ratio, 2.24; 95% CI, 1.38-3.65; P Ͻ 0.01). Grade 2 to 4 acute GVHD developed in 48 patients (41%) in the CYA-MTX group and in 16 (35%) in the CYA-PRED group (P = NS). In separate multivariate models that included the type of GVHD prophylaxis, CMV status, sex, and disease status at transplantation, transplants with a CMV mismatch were more likely (risk ratio 1.88, 95% CI 1.12-3.13) to have chronic GVHD (P = 0.016). Sex and disease status at transplantation were not significantly associated with the incidence of chronic GVHD. Although there was a baseline difference between the groups in terms of conditioning therapy, the increased risk of chronic GVHD with CYA-PRED was significant, using a Cox proportional hazards analysis (P Ͻ 0.001), even after adjusting for the conditioning therapy. Among the 163 patients surviving beyond 60 days after transplantation, the type of prophylaxis had no significant effect on relapse-free survival (P = 0.26) (Figure 2 ). However, the development of chronic GVHD had a protective effect from relapse, and this effect was statistically significant (relative risk, 0.315; 95% CI, 0.139-0.713; P = 0.006). In univariate analysis, PRED for GVHD prophylaxis was significantly associated with increased mortality (relative risk, 1.97; 95% CI, 1.12-3.45; P = 0.02). In a multivariate model taking into account development of chronic GVHD, PRED treatment remained a significant risk factor for increased mortality (relative risk, 2.15; P = 0.013), although development of chronic GVHD itself was not significant for increased mortality (P = 0.410). Eighty patients in the CYA-MTX group (68%) and 25 in the CYA-PRED group (55%) were alive at the time of the analysis. Overall survival between the two prophylaxis groups was not significantly different when all the patients having transplant were considered (P = 0.2) (Figure 3) . Relapse of the primary disease and infection were the most common causes of death in this series of patients (Table 3) . Five patients died of respiratory failure: four of progressive bronchiolitis obliterans and one of restrictive disease due to severe skin GVHD. Gastrointestinal hemorrhage, intracranial hemorrhage, and drug-induced liver failure caused one death each.
Discussion
This study retrospectively examined the effect on the incidence of chronic GVHD of two commonly used immunosuppressive regimens for the prevention of GVHD in recipients of HLA-identical marrow transplants. In this study, a group of patients who had a transplant between 1994 and 1997 had received mostly CYA-PRED for prophylaxis because of a shift in institutional policy influenced by concerns about increased incidence of venoocclusive disease with the CYA-MTX regimen. This group was compared with a group of patients receiving CYA-MTX who had transplants over a longer period. Several prospective studies have shown that the combination of CYA and MTX is superior to either agent used alone. 10, 29, 30 In most studies, MTX-containing regimens have been associated with slower engraftment, presumably because of its myelosuppressive effects. The mucositis associated with MTX also adds to morbidity in the immediate post-trans- Table 3 Cause of death of patients in two treatment groups Bone Marrow Transplantation plant period. These factors in combination with the increased concern about hepatic veno-occlusive disease in patients receiving CYA and MTX have led many transplant centers to reduce the use of MTX in post-transplant immunosuppression. 23, 31 The combination of CYA and PRED has been shown to be an effective alternative. The effect of this combination on the incidence of chronic GVHD is unclear: the results of some studies have suggested an increase in the incidence of chronic GVHD 13, 20 and others have suggested the opposite. 19 We retrospectively examined the influence of the selection of prophylactic immunosuppressive drugs on the incidence of chronic GVHD.
In our study, prophylaxis with CYA-PRED was associated with a higher risk of development of chronic GVHD (risk ratio 3.5; 95% CI 2.213-5.406). At 1 year after transplantation, the cumulative probability of chronic GVHD in the CYA-PRED group was nearly double that in the CYA-MTX group. Our results confirm the previous observations that the incidence of chronic GVHD increased with treatment with a combination of CYA and PRED. The reasons for this increase are not clear. Acute GVHD is known to predispose to chronic GVHD. 32 However, this alone cannot explain the increased incidence of chronic GVHD in our study, because PRED prophylaxis remained an independent risk factor even after accounting for the incidence of acute GVHD. The increased incidence of de novo chronic GVHD also argues against this explanation. Our study also demonstrated a four-fold higher risk for development of extensive chronic GVHD among patients in the CYA-PRED group 2 years post transplantation. Development of extensive GVHD, especially with involvement of the lung and skin, contributes to considerable long-term morbidity in these patients. Patients with bronchiolitis obliterans and severe sclerodermatous skin changes often have an extremely poor quality of life despite having been cured of their disease. Also, chronic GVHD developed at an earlier time after transplantation in this group than in the CYA-MTX group.
Studies in which PRED was added to a combination of CYA and MTX have shown an increase in the incidence of chronic GVHD, suggesting that PRED may interfere with the development of immune tolerance achieved with the administration of MTX.
14 MTX is believed to be responsible for selectively destroying the T cells that proliferate in response to host alloantigens. Possibly, PRED may interfere with this step by preventing the T cell proliferation induced by exposure to host alloantigens. This would render MTX ineffective. After the dose of PRED has been tapered, the host-reactive T cells still present in the recipient can initiate the chronic GVHD reaction. The administration of PRED after transplantation, starting on day 15, has been shown to be associated with a lower incidence of chronic GVHD.
14 This supports the observation of increased chronic GVHD among recipients who have PRED therapy initiated earlier after transplantation.
The mechanisms involved in the prevention of tolerance have not been identified clearly. Studies involving BMT in mice have proved that thymic epithelial cells and antigenpresenting cells have a key role in the induction of donor T cell tolerance. 33 Host lymphocytes that survive the conditioning regimen may also have a role in the induction of tolerance by down-regulating the graft-versus-host immune response. Mixed allogeneic chimerism can be induced in irradiated mice by infusion of a mixture of T cell-depleted (TCD) syngeneic marrow and TCD allogeneic marrow. Complete immunologic cross-tolerance across major histocompatibility barriers in these mice results in the complete absence of GVHD and immunocompetence. 34 The anti-GVHD effect of TCD syngeneic marrow is probably related to development of suppressor cells from the syngeneic marrow component. 35 A similar mechanism is believed to be responsible for the decreased GVHD associated with nonlethal conditioning using a combination of anti-CD4 and CD8 monoclonal antibodies, followed by low-dose TBI and high-dose thymic irradiation. The host cells that escape this conditioning contribute to the formation of suppressor cells. 35 Persisting host lymphoid cells may also induce tolerance by clonal deletion. 36 Parallel situations also exist in clinical BMT. Patients with aplastic anaemia receiving allogeneic matched transplants who maintain a mixed chimeric state after transplantation have a decreased incidence of acute GVHD. 37 Destruction of host lymphoid cells by corticosteroids given as part of GVHD prophylaxis could potentially contribute to the increased incidence of chronic GVHD. This may also explain the increased incidence of chronic GVHD that occurs after BMT in patients with aplastic anaemia who have extended corticosteroid therapy before transplantation. 32 Animal studies have shown that the onset of autoimmune disease is often preceded by periods of lymphocytopenia that could potentially predispose to infection. 33 Polysaccharides and other molecules from the infectious agents could act as adjuvants in potentiating the T cell response to foreign antigens.
As observed in previous studies, acute GVHD was an independent predictor for development of chronic GVHD in our patients. Infusion of marrow from a CMV seropositive donor into a CMV seronegative host was associated with a higher risk of chronic GVHD. Donor CMV positivity has been shown in several studies to increase the risk of chronic GVHD. 3, 38, 39 However, Ljungman et al 40 did not find any correlation between CMV status and the development of chronic GVHD. CMV infections in the marrow recipient after transplantation have also been linked to an increased incidence of chronic GVHD. 41, 42 In our group of patients, those who were conditioned with a combination of BU and CY were more likely to receive CYA-PRED for GVHD prophylaxis because of concern about increased risk of veno-occlusive disease with BU and CY. Increased risk of chronic GVHD has been observed in patients undergoing allogeneic BMT with BU and CY conditioning, compared with conditioning with CY and TBI. 43 However, the increased risk of chronic GVHD with CYA-PRED seen in our study was still significant after adjusting for this difference.
Development of chronic GVHD tended to protect the recipients from relapse, which would be explained by the graft-versus-leukaemia effect afforded by chronic GVHD. 44 The relapse-free survival and overall survival did not differ significantly between our two treatment groups, and this could be related to the increased mortality that occurred among patients developing GVHD. Prophylactic treatment of GVHD with PRED was associated with an increased risk of death, even after accounting for the development of chronic GVHD. This could be related to the increased risk of infections that has been reported with PRED therapy. 18 Awareness of the risk of corticosteroid therapy is important when choosing a GVHD prophylactic regimen in patients undergoing blood and marrow transplantation. The increased risk of chronic GVHD with the use of PRED should be balanced with the potential risk of increased veno-occlusive disease that occurs with MTX-containing regimens. 23, 31 CYA-PRED might be a credible alternative to CYA-MTX in patients with preexisting liver dysfunction, because they are at a higher risk for veno-occlusive disease. 31 In comparing the incidence of chronic GVHD in different studies, it is important to consider the type of prophylaxis used. An increased incidence of chronic GVHD has been associated with allogeneic peripheral stem cell transplants, compared with that of allogeneic BMT, in several case control studies, but PRED was part of the GVHD prophylactic regimen in only one of these studies. [45] [46] [47] [48] 
